Tearsheet

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow


0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
Trading close to highs
Dist 52W High is -1.4%
Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 221x
1 Attractive yield
FCF Yield is 7.8%
Weak multi-year price returns
2Y Excs Rtn is -51%, 3Y Excs Rtn is -102%
Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8%
2 Low stock price volatility
Vol 12M is 40%
  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.7%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Precision Medicine. Themes include AI in Healthcare Management, Health Data Analytics, Show more.
  Key risks
NVST key risks include [1] significant geopolitical and currency exposure due to generating approximately 70% of its revenue internationally and [2] the negative impact of China's Volume-Based Procurement (VBP) policy on its orthodontics segment.
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 11%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
1 Attractive yield
FCF Yield is 7.8%
2 Low stock price volatility
Vol 12M is 40%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Precision Medicine. Themes include AI in Healthcare Management, Health Data Analytics, Show more.
4 Trading close to highs
Dist 52W High is -1.4%
5 Weak multi-year price returns
2Y Excs Rtn is -51%, 3Y Excs Rtn is -102%
6 Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 221x
7 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.8%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.7%
9 Key risks
NVST key risks include [1] significant geopolitical and currency exposure due to generating approximately 70% of its revenue internationally and [2] the negative impact of China's Volume-Based Procurement (VBP) policy on its orthodontics segment.

Valuation, Metrics & Events

NVST Stock


Why The Stock Moved


Qualitative Assessment

AI Generated Analysis | Feedback

For Envista (NVST), a significant stock movement around 3.2% can be attributed to several factors surrounding its recent financial performance and outlook. While precise daily fluctuations for a future period cannot be provided, the company's financial results for the fourth quarter and full year 2024, reported on February 10, 2025, offer insights into factors that would drive such movements. Following this announcement, Envista's shares notably climbed by 5.9%. Here are five key points explaining significant stock movements for Envista (NVST): 1. 1. Exceeded Earnings Estimates: Envista reported adjusted earnings per share (EPS) of 24 cents for the fourth quarter of 2024, surpassing the Zacks Consensus Estimate of 23 cents by 4.3%.

2. 2. Strong Revenue Performance: The company's revenues for the fourth quarter of 2024 reached $652.9 million, an increase of 1.1% year-over-year, and also exceeded the Zacks Consensus Estimate of $646.28 million by 1.1%.

3.

Show more

Stock Movement Drivers

Return vs. Risk


Price Returns Compared

 202020212022202320242025Total [1]
Returns
NVST Return14%34%-25%-29%-20%14%-26%
Peers Return40%6%-2%12%-7%-14%31%
S&P 500 Return16%27%-19%24%23%14%108%

Monthly Win Rates [3]
NVST Win Rate67%50%50%42%50%50% 
Peers Win Rate60%58%50%57%43%43% 
S&P 500 Win Rate58%75%42%67%75%73% 

Max Drawdowns [4]
NVST Max Drawdown-60%-2%-28%-37%-36%-23% 
Peers Max Drawdown-27%-16%-31%-14%-22%-34% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 


[1] Cumulative total returns since the beginning of 2020
[2] Peers: MSA, MMSI, HAE, IART, WST.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)

How Low Can It Go

Unique KeyEventNVSTS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-58.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven141.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-64.1%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven178.8%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven283 days148 days

Compare to MSA, MMSI, HAE, IART, WST


In The Past

Envista's stock fell -58.6% during the 2022 Inflation Shock from a high on 3/21/2022. A -58.6% loss requires a 141.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Envista (NVST)

Better Bets than Envista (NVST)

Trade Ideas

Select past ideas related to NVST. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.3%16.3%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-7.1%-7.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.6%3.6%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
1.6%1.6%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
14.1%14.1%-5.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
CRL_11142025_Dip_Buyer_FCFYield11142025CRLCharles River Laboratories InternationalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
16.3%16.3%-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE11142025GDRXGoodRxDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-7.1%-7.1%-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025ASTHAstrana HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.6%3.6%-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG11142025SGRYSurgery PartnersDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
1.6%1.6%-1.4%
TFX_11072025_Dip_Buyer_FCFYield11072025TFXTeleflexDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
14.1%14.1%-5.1%

Recent Active Movers

Recent Active Movers

More From Trefis

Peer Comparisons for Envista

Peers to compare with:

Financials

NVSTMSAMMSIHAEIARTWSTMedian
NameEnvista MSA Safe.Merit Me.Haemonet.Integra .West Pha. 
Mkt Price21.85158.4887.2379.9813.04269.1383.61
Mkt Cap3.66.25.23.81.019.44.5
Rev LTM2,6221,8641,4771,3281,6433,0181,753
Op Inc LTM21939116823131631225
FCF LTM262283204256-14379259
FCF 3Y Avg25117314814744374161
CFO LTM30034926828989694295
CFO 3Y Avg297228198212131721220

Growth & Margins

NVSTMSAMMSIHAEIARTWSTMedian
NameEnvista MSA Safe.Merit Me.Haemonet.Integra .West Pha. 
Rev Chg LTM4.7%3.3%11.4%-2.5%5.0%4.9%4.8%
Rev Chg 3Y Avg0.8%7.8%9.2%7.2%1.7%1.3%4.5%
Rev Chg Q11.5%8.3%13.0%-5.3%5.6%7.7%8.0%
QoQ Delta Rev Chg LTM2.7%2.0%3.1%-1.4%1.3%1.9%2.0%
Op Mgn LTM8.3%21.0%11.4%17.4%1.9%20.9%14.4%
Op Mgn 3Y Avg9.3%21.3%11.0%14.6%4.3%21.8%12.8%
QoQ Delta Op Mgn LTM1.2%-0.3%0.0%1.2%1.2%-0.1%0.6%
CFO/Rev LTM11.4%18.7%18.1%21.8%5.4%23.0%18.4%
CFO/Rev 3Y Avg11.6%12.4%14.4%16.4%8.3%24.6%13.4%
FCF/Rev LTM10.0%15.2%13.8%19.3%-0.9%12.6%13.2%
FCF/Rev 3Y Avg9.8%9.4%10.8%11.3%2.9%12.7%10.3%

Valuation

NVSTMSAMMSIHAEIARTWSTMedian
NameEnvista MSA Safe.Merit Me.Haemonet.Integra .West Pha. 
Mkt Cap3.66.25.23.81.019.44.5
P/S1.33.63.31.70.76.32.5
P/EBIT17.616.827.29.6-2.431.317.2
P/E221.124.141.613.8-2.238.531.3
P/CFO11.319.318.48.012.327.315.4
Total Yield0.5%4.5%2.4%7.3%-45.0%2.8%2.6%
Dividend Yield0.0%0.3%0.0%0.0%0.0%0.2%0.0%
FCF Yield 3Y Avg6.8%2.5%2.9%5.1%1.7%1.7%2.7%
D/E0.50.10.20.51.80.00.3
Net D/E0.10.10.10.41.6-0.00.1

Returns

NVSTMSAMMSIHAEIARTWSTMedian
NameEnvista MSA Safe.Merit Me.Haemonet.Integra .West Pha. 
1M Rtn14.3%1.9%1.7%7.6%11.2%2.6%5.1%
3M Rtn4.1%-5.9%5.5%60.1%-11.9%4.9%4.5%
6M Rtn17.4%-3.4%-6.2%14.2%9.5%23.7%11.8%
12M Rtn13.6%-5.0%-11.9%-2.5%-43.4%-19.2%-8.4%
3Y Rtn-33.7%26.5%22.4%2.1%-76.5%19.9%11.0%
1M Excs Rtn13.6%1.1%0.9%6.9%10.4%1.8%4.4%
3M Excs Rtn2.6%-8.1%2.4%55.0%-16.6%4.3%2.5%
6M Excs Rtn5.0%-15.8%-18.5%1.8%-2.9%11.3%-0.6%
12M Excs Rtn1.1%-19.0%-26.2%-12.6%-56.8%-29.3%-22.6%
3Y Excs Rtn-101.6%-46.1%-50.1%-70.6%-145.4%-56.1%-63.3%

Financials

Segment Financials

Assets by Segment

$ Mil20242023202220212020
Specialty Products & Technologies3,2783,4763,4983,7733,662
Equipment & Consumables2,3392,4551,9462,1782,257
Corporate and other9896561,118924239
Held for Sale  12  
Total6,6056,5876,5746,8766,158


Price Behavior

Short Interest

Short Interest: As Of Date11282025
Short Interest: Shares Quantity10,583,006
Short Interest: % Change Since 11152025-1.7%
Average Daily Volume1,654,645
Days-to-Cover Short Interest6.40
Basic Shares Quantity166,100,000
Short % of Basic Shares6.4%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/29/20250.8%0.9%4.0%
7/31/202510.3%6.4%12.1%
5/1/20254.0%8.8%10.8%
2/5/20255.9%1.4%-10.4%
10/30/20249.0%13.8%15.9%
8/7/20247.8%13.1%14.0%
5/1/20240.3%-4.7%-2.0%
2/7/2024-7.4%-8.7%-12.4%
...
SUMMARY STATS   
# Positive161413
# Negative81011
Median Positive4.9%7.4%5.9%
Median Negative-6.0%-5.0%-8.0%
Max Positive10.3%13.8%21.0%
Max Negative-7.6%-9.7%-17.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
93020251030202510-Q 9/26/2025
6302025731202510-Q 6/27/2025
3312025501202510-Q 3/31/2025
12312024213202510-K 12/31/2024
93020241030202410-Q 9/27/2024
6302024807202410-Q 6/28/2024
3312024501202410-Q 3/29/2024
12312023215202410-K 12/31/2023
93020231101202310-Q 9/29/2023
6302023802202310-Q 6/30/2023
3312023503202310-Q 3/31/2023
12312022216202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022803202210-Q 7/1/2022
3312022504202210-Q 4/1/2022
12312021224202210-K 12/31/2021